Comparison of regimens for home-based early medical abortion in Tunisia and Vietnam
- August 29th, 2012
- Medical Abortion
- Blum, J., Raghavan, S., Dabash, R., Ngoc, N.T.N., Chelli, H., Hajri, S., Conkling, K., Winikoff, B.
Int J Gynaecol Obstet; 2012 Aug; 118(2):166-71; doi:10.1016/j.ijgo.2012.03.039
This trial sought to evaluate the potential advantages of combined mifepristone–misoprostol versus misoprostol-only for earlymedical abortion. The study was double-blind randomized placebo controlled and enrolled 441 pregnant women (<63 days LMP). The mifepristone–misoprostol group (n=220) received 200 mg of mifepristone on day 1 and 800 μg buccal misoprostol followed by placebo 3 hours later on day 2. The misoprostol-only group (n=221) received placebo on day 1 and 1600 μg of misoprostol (2 doses of 800 μg, given 3 hours apart) on day 2. The results demonstrated that the combined regimen was significantly more effective than the misoprostol-only protocol for early medical abortion.